Overview

A Study of CAD106 and CNP520 Versus Placebo in Participants at Risk for the Onset of Clinical Symptoms of Alzheimer's Disease

Status:
Terminated

Trial end date:
2020-04-30

Target enrollment:

Participant gender:

Summary

The purpose of this study was to test whether two investigational drugs called CAD106 and CNP520, administered separately, could slow down the onset and progression of clinical symptoms associated with Alzheimer's disease (AD) in participants at the risk to develop clinical symptoms based on their age and genotype.

Phase:

Phase 2/Phase 3

Details

Lead Sponsor:

Novartis Pharmaceuticals

Collaborators:

Alzheimer's Association
Amgen
Banner Alzheimer's Institute
National Institute on Aging (NIA)

Treatments:

CNP520